BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Tilt taking next-gen oncolytic virus candidate to phase II with €10 million round
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tilt taking next-gen oncolytic virus candidate to phase II with €10 million round
June 14, 2022
By
Nuala Moran
No Comments
Tilt Biotherapeutics Ltd. has closed a €10 million (US$10.7 million) round, enabling it to start two phase II trials of its armed oncolytic virus, TILT-123, in combination with checkpoint inhibitor drugs.
BioWorld
Financings